Novo Nordisk’s Q1 Revenue Grows 24%; Wegovy Sales Surge

Novo Nordisk announced its Q1 2024 financial results on Thursday, reporting a 24% year-on-year revenue increase—driven primarily by the continued strong performance of Ozempic (semaglutide), its blockbuster treatment for type 2 diabetes, and a sharp sales surge for Wegovy (semaglutide), its obesity-treatment drug. In Q1, the Danish pharmaceutical company generated over $9.37 billion in revenue—up from approximately $7.65 billion in the same period of 2023. Novo Nordisk posted net profit exceeding $3.64 billion and earnings per share of approximately $0.81—a 29% increase year-on-year. Lars Fruergaard Jørgensen, CEO of Novo Nordisk, stated in a press release that the company was “pleased” with the quarter’s growth, “primarily driven by increasing demand for our GLP-1-based treatments for diabetes and obesity.” Ozempic was Novo Nordisk’s top-performing asset this quarter, generating nearly $4.3 billion in revenue—a 35% year-on-year increase at constant exchange rates. Wegovy—a distinct formulation of the GLP-1 analogue semaglutide, approved for chronic weight management—generated over $1.34 billion in Q1 sales, representing a staggering 107% increase compared to Q1 2023. According to CNBC, during Thursday’s media conference call, CFO Karsten Munk Knudsen acknowledged Wegovy’s “very good growth” in Q1, noting that it offset price declines in the North American market—where prices are expected to fall further amid rising volume and intensifying competition.

Despite Multi-Million-Dollar Salaries, Top Executives Are Resigning En Masse—Why Is the Pharmaceutical Industry Experiencing an Executive Exodus?

· In September 2023, Ugur Sahin, CEO of U.S.-based biopharmaceutical company BioNTech, announced his resignation as CEO but will remain as co-founder. Sahin’s departure is reportedly intended to refocus on early-stage R&D and advance equitable global distribution of COVID-19 vaccines. 6. On March 15, Albert Bourla, CEO of Pfizer, announced his resignation, concluding his 24-year leadership tenure at the company. · In March 2023: Chen Xi, General Manager of Pfizer China, resigned after a decade with the company; he subsequently joined a biopharmaceutical firm. 7. On March 23, Joseph Jimenez, CEO of Novartis, announced his resignation, ending his 28-year leadership at the company. · In April 2023: Li Bingrong, General Manager of Novartis China, resigned after ten years with the company; he later joined an innovative pharmaceutical company. 8. In January 2023: Zhang Wenjun, General Manager of Sanofi China, resigned after 15 years with Sanofi; he subsequently joined an innovative pharmaceutical company. On April 20, Severin Schwan, CEO of Sanofi, announced his resignation for personal reasons. 9. On May 1, Brent Saunders, CEO of Merck & Co., resigned for personal reasons. 10. On May 15, Alex Gorsky, CEO of Johnson & Johnson, resigned for personal reasons. 11. On June 2, the CEO of Novo Nordisk resigned. 12. On June 12, Vas Narasimham, CEO of Celgene, resigned for personal reasons. 13. In July 2023, Japanese pharmaceutical company Otsuka Pharmaceutical announced that its Chief Operating Officer (COO) and Chief Financial Officer (CFO) would be stepping down. Their departures are viewed as part of an internal restructuring aimed at improving operational efficiency and profitability—and may impact the company’s stability. 14. In June 2023: Zhang Ning, Senior Vice President and Chief Commercial Officer of BeiGene, resigned. It is reported that Zhang Ning will join a biotechnology company. 15. In September 2022: Li Xiaodong, General Manager of GSK China, resigned after 15 years with GlaxoSmithKline; he subsequently joined a biopharmaceutical company. 16. In June 2023, Dr. Robert Steffenhagen, Chief Scientific Officer of German pharmaceutical company Merck & Co., announced his resignation. Having served as CSO for a decade, his departure may influence the company’s future R&D strategy. 17. In September 2023, Dr. Peter Marks, Chief Medical Officer of Swiss pharmaceutical company Roche, resigned for personal reasons.

Novo Nordisk's CFO Karsten Munk Knudsen to leave company

11 hours ago

Novo Nordisk announced that CFO Karsten Munk Knudsen will step down, succeeded by Luigi La Corte. The Danish pharmaceutical firm confirmed the executive change on Wednesday.

reuters

2026-06-12

European Stocks Rally as Oil Prices Drop on US-Iran Deal Hopes

2026-11-03

Novo Nordisk's CFO Karsten Munk Knudsen to leave company

FAQ

Scan to get the App